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Tumorigenesis can be seen as an evolutionary process, in which the transformation of a
normal cell into a tumor cell involves a number of limiting genetic and epigenetic events,
occurring in a series of discrete stages. However, not all mutations in a cell are directly
involved in cancer development and it is likely that most of them (passenger mutations)
do not contribute in any way to tumorigenesis. Moreover, the process of tumor evolution
is punctuated by selection of advantageous (driver) mutations and clonal expansions.
Regarding these driver mutations, it is uncertain how many limiting events are required
and/or sufficient to promote a tumorigenic process or what are the values associated
with the adaptive advantage of different driver mutations. In spite of the availability of
high-quality cancer data, several assumptions about the mechanistic process of cancer
initiation and development remain largely untested, both mathematically and statistically.
Here we review the development of recent mathematical/computational models and
discuss their impact in the field of tumor biology.
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INTRODUCTION
Since observations of aberrant mitosis in cancer cells by David
von Harsermann, in the late nineteenth century and the pro-
posal that chromosomal abnormalities are fundamental to cancer
development by Theodor Boveri in early twentieth century, it
is well-established that cancer is a genetic disease of somatic
cells. During this period, experimental support of the genetic
hypothesis came from the evidence that ionizing radiation and
some chemical components, already known to be carcinogenic,
could act as mutagenic agents. According to Knudson (2001), the
term “somatic mutation” was first applied to cancer by Ernest
Tyzzer in 1916, many years before the elucidation of the role of
DNA in heredity. But it was only in 1976 when Peter Nowell
convincingly stated that cancer is a clonal disease subject to
Darwinian evolution, a concept that is now currently established
(Nowell, 1976). Two interesting discussions of the initial theo-
ries of cancer can be found in the books of Weinberg (2006) and
Frank (2007).
Since then, our understanding of the molecular mechanisms
underlying tumor initiation and development, involving many
specific genes and si pathways, has improved. For example,
Hanahan and Weinberg (2000) have suggested that acquisition
of six types of molecular alterations, or hallmarks—(1) self-
sufficiency of proliferative signals, (2) insensitivity to anti-growth
signals, (3) evasion of apoptosis, (4) limitless replicative potential,
(5) sustained angiogenesis, and (6) active invasion and metas-
tasis, would progressively drive a population of normal cells to
become a cancer (Hanahan and Weinberg, 2000). Crucial to the
development of these molecular alterations is genome instabil-
ity, which generates genetic diversity, which in turn, can further
contribute to cancer development (Loeb, 1991). Recently, the
same authors added two other features to these hallmarks: the
capability to reprogramming energetic metabolism and evading
immune surveillance (Hanahan andWeinberg, 2011).
The elucidation of the above mechanisms strengthened the
view of cancer as a product of a Darwinian evolutionary pro-
cess, i.e., a somatic cellular selection, in which (1) the cellular
population presents a range of inheritable genetic variations,
caused by random mutational processes, and (2) natural selec-
tion, where faster dividing cells have an advantage over their
normal neighbors. At population level, somatic cells proliferate in
an unconstrained manner and compete for nutrients and space.
At molecular level, the genome accumulates somatic mutations
that allow the cell to reproduce more efficiently and the selec-
tion of cells with a higher fitness drives tumorigenesis (Nowell,
1976). Clonal selection is a key concept in tumor biology since
it can affect not only replication rate and survival but also inva-
sion capacity and resistance to therapies. Experimental evidences
obtained in the last 40 years and the development of (next gen-
eration) sequencing technologies—that allowed identification of
virtually all genetic alterations in a cancer cell, have stimulated
the use of evolutionary-based approaches in the study of can-
cer. First, clonal expansions and retractions indeed occur within
tumors [recently reviewed by Greaves andMaley (2012)]. Second,
tumors have been characterized as highly heterogeneous both at
the phenotype and genotype levels (Wood et al., 2007; Jones et al.,
2008; Parsons et al., 2008). Third, recent studies have confirmed
that metastatic lesions are expansions of clones derived from the
primary tumor (Jones et al., 2008; Yachida et al., 2010).
Somatic mutations in any cellular genome, either induced by
external source or spontaneously occurring during the mitotic
replication, may comprise different types of DNA alterations.
These include substitutions, insertions or deletions of one
base (single nucleotide polymorphism), or segments of DNA;
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rearrangements; amplification, or deletions that sometimes may
comprise the whole genome (polyploidy). In addition, the cell
genome may acquire entire sequences from exogenous sources,
and epigenetics changes, which alter chromatin structure, can also
be subject to the same selection forces as genetic events. However,
not all mutations in the cell genome are directly involved in
cancer development and it is likely that most of them do not con-
tribute in any way. To relate these capabilities, the terms “driver”
and “passenger” mutations were coined (Stratton et al., 2009).
A driver mutation is directly implicated as the cause of the tumor
process—it confers a growth advantage to tumor cells and is
positively selected in the environment of the tissue where the
cancer appears. Conversely, a passenger mutation does not con-
fer growth advantage and not contribute to the development of
cancer. Today, one of the great challenges is cancer biology is to
discriminate between driver, which are potential targets for ther-
apy, and passenger mutations (Beerenwinkel et al., 2007; Wood
et al., 2007; Jones et al., 2008).
The availability today of large datasets on different aspects of
tumor biology has provided opportunities for the use of mathe-
matical models in oncology, which in turn has provided a more
quantitative understanding of the dynamics of tumorigenesis.
MATHEMATICAL MODELING
Although mathematical modeling has had a primary role in other
areas of science, like physics and engineering, the application of
mathematical techniques for generating insights into biological
problems has been far less common. Nevertheless, this scenario
is beginning to change, with the application of methods from
“hard science”—i.e., statistics, computational and mathematical
techniques, control engineering, and dynamic systems analysis to
address biological data and questions. The mathematical inves-
tigation of cancer has not had a very long history—it started
in 1950s, aiming to derive the “basic laws” regarding the tumor
dynamics, to organize information and to elaborate a comprehen-
sive framework for hypothesis testing (Komarova, 2005; Attolini
andMichor, 2009; Byrne, 2010; Vineis et al., 2010). The acknowl-
edgment of these elementary principles can improve our under-
standing of tumor biology and ultimately can be used to interfere
on the mechanisms of tumor initiation, development, treatment,
and resistance, in the new area of translational medicine.
Broadly, these models can be organized in three major areas:
(1) epidemiology and statistical models, (2) mechanistic growth
models, and (3) evolutionary dynamics models (Table 1). The
first ones use statistics and incidence curves to create models
to explain population data. The carcinogenesis process is then
explained by a series of distinct genetic events that cumulates
on the tumor development. The second approach uses biological
knowledge and a variety of methods to model tumor dynamics,
from molecular mechanisms to population level. The carcino-
genic process is also understood as a series of distinct events,
but those are expanded to epigenetics and genome instability
as well. The third group looks at cancer progression within an
ecological and evolutionary biology approach, and nowadays is
heavily based on cancer genomic data. Obviously, this is just
a way to categorize the models, and there is a temporal and
conceptual overlap among them. For example, the tumorigenic
progress throughmultiple discrete stages is a common underlying
mechanism in all models. However, they are different in the
way they explain tumor development. In the first model, the
occurrence of a mutational event would be a sufficient condi-
tion, while on the third model, this would be just a necessary
but not sufficient condition. Therefore, we define a model as a
theory established based on observations and premises that incor-
porates explanatory mechanisms. Generally, a well-constructed
theoretical model encompasses interesting biological insights and
a reasonable predictive power, and it is based on experimental
research and observations. Here we will briefly discuss two dis-
tinct approaches, focusing on epidemiological and evolutionary
models. This is not intended to be an exhaustive review of the
subject, but rather a focused discussion on a limited number of
papers in order to illustrate how theoretical representations can
assist the improvement of biological knowledge.
THE “STAGE MODELS” OF CANCER—EXPERIMENTAL AND
EPIDEMIOLOGICAL DATA
Early models that aimed to explain the carcinogenic process
were based on experimental and epidemiological data. In the
beginning of the twentieth century, experimental studies were
usually performed in animal models to identify chemicals that
were able to cause cancer. Compounds with strong carcino-
gen effects like PAHs (polycyclic aromatic hydrocarbons) were
painted on the animal skin and tumor growth was analyzed.
The researchers observed that the sequential application of two
distinctive carcinogens frequently produced a greater ratio of can-
cer development than the application of an isolated one. In a
Table 1 | Theoretical models on carcinogenesis.
Epidemiological Mechanicistic Evolutionary
Data Statistics (incidence curves, epidemics) Experimental (molecular to
populational)
Genomic
Biological
mechanism—main focus
Multiple distinct genetic events Genetic and epigentic events,
genome instability
Adaptive advantage, “Darwinian
selection”
Background Multi-stage model Multi-stage model Evolutionary dynamics
Main reference Armitage and Doll (1954, 1957) Several Beerenwinkel et al., 2007; Bozic
et al., 2010
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series of studies, Berenblum and Shubik tested the idea that two
distinct tumor phase were stimulated by carcinogen—the “initi-
ation” and “promotion” stages, and in 1949, after experimental
verification, they proposed the “Two-stage” model of carcinogen-
esis (Berenblum and Shubik, 1949). In general, the initiators were
the compounds that predispose the tumor development—and
for this reason, were considered mutagenic, while promoters
were the non-reactive compounds (non-mutagenic)—considered
mitogenic, stimulating cell cycle, and tumor growth. Although
this theory could not be extensively verified experimentally, the
two-stage theory provided the first evidence in favor of the idea
of multiple stages of cancer progression.
Later on, another type of evidence, based on epidemiolog-
ical data of cancer mortality, allowed the development of the
multistage theory (MST) of cancer development. Epidemiological
studies indicated that (1) cancer incidence often increased rapidly
with age, (2) simple patterns could be observed at the popula-
tion level, although what happened to any particular individual
appeared to be highly stochastic. This age-specific uniformity
contrasted with the diversity of genetic and environmental mech-
anisms underlying carcinogenesis, such as the inheritance of
genetic variants and exposure of carcinogenic agents. The chal-
lenge was to elucidate the essential mechanisms that gave rise
to the cancer process by observing the population data, and
try to determine to which extension each one of these fac-
tors could modify the quantitative properties of age-specific
incidence.
Many studies attempted to derive the dynamics of cancer
progression from epidemiological data (Fisher and Hollomon,
1951; Nordling, 1953; Stocks, 1953) and indeed they supported
the idea that carcinogenesis would require “n” mutational steps.
Extending these studies and analyzing incidence curves for a
variety of non-endocrine carcinomas, which showed that tumor
incidence increased with the sixth power of age, Peter Armitage
and Richard Doll, proposed the “Multistage Theory” (MST), in
1954 (Armitage and Doll, 1954, 1957). The theory stated that
cancer could arise from normal tissues through a series of mul-
tiple stages, assuming that (1) the changes of state are discrete,
(2) each stage is stable, and (3) the changes must proceed in a
unique order. The theory also explained the linear relationship
between carcinogenesis dose and incidence and the long time
delay between carcinogen exposure and transformation, observed
in experimental studies. Moreover, the model indicates that can-
cer incidence would increase approximately with a power of age,
tn−1, where t represents age and n, the number of rate-limiting
carcinogenic events required for transformation. Fitting the for-
mula I(t) = ktn—where I is the age-specific incidence and k is
a constant of proportionality, to incidence curves for most of
the common adult cancers, Armitage and Doll suggested that n
should account to 6–7 distinct events. These successive events
are biological changes (not necessarily mutations) that give rise
to a number of cells with a significant growth advantage, which
will develop in an apparent tumor—excluding other processes
that could lead to invasion and metastasis. In theoretical mod-
els, the term mutation or “event” is usually applied to any genetic
modification—such as point mutation, insertion, deletion, chro-
mosome rearrangement, mitotic recombination, and loss or gain
of whole chromosome or parts of it—but it can be used to denote
a non-mutagenic events as well.
The importance of a model can be measured by the confirma-
tion of its predictions and several incidence curves were observed
to match the dynamic predict by MST—about seven steps and
constant rates of transition, providing an excellent description
of cancers of the colon, stomach, and pancreas. Nevertheless,
other tumors, including breast and prostate cancer, failed to
fit this model, indicating a different type of tumor progression
dynamics—with fewer events and higher rates of limiting events.
Two studies, from Ashley (1969) and Knudson (1971), addition-
ally provided an empirical evidence for the MST, although they
modified the original conception of multistage model, to incor-
porate new observed conditions. The rational was: “if somatic
mutation is the normal cause of progression, then individuals
who inherit a mutation would have one less step to pass before
cancer arises” (Frank, 2007). In the log-log plot representation,
one less step shifts the incidence curve to earlier ages and reduces
the slope. The analysis of the cancer incidence in normal indi-
viduals and individuals carrying a mutation that could lead to
colorectal cancer was performed by Ashley (1969), and the results
confirmed the model hypothesis—predisposed individuals pre-
sented cancer in earlier ages. Few years later, Knudson (1971)
observed the same shift on the incidence of retinoblastoma,
when he analyzed individuals with inherited and non-inherited
mutations—and proposed the concept of the tumor suppressor
gene (TSG). Cancer would emerge when both alleles of TSG are
inactivated. In the first group of children, one allele is already
inactivated in their germ line, while the second allele is inacti-
vated by somatic mutation. This is known as Knudson’s two-hits
hypothesis: it takes two hits to inactivate a TSG. Beyond those
models, the MST has been extensively refined, in order to fit data
from different bases and assumptions (Armstrong and Doll, 1975;
Day and Brown, 1980; Knudson, 2001; Luebeck and Moolgavkar,
2002).
Although Armitage and Doll (1957) have not identified the
precise mechanisms underlying carcinogenesis, its major contri-
bution was the development of a conceptual basis that allowed
one to relate incidence data, at a population level, to a basic car-
cinogenic process at the individual level, i.e., the limiting multiple
events. It is important to note that the model was proposed in
a time when a minimum knowledge about the molecular and
cellular mechanisms of cancer was available. This illustrates the
importance of good and reasonable assumptions, i.e., the theoret-
ical framework, in elaborating a model. However, without specific
knowledge of these factors, we can just estimate the number of
crucial events. Actually this is the major drawback of the MST,
i.e., its incapacity to link stage identification with the functional
changes underlying tumor progression.
This scenario is changing fast, with the development of high
throughput technologies, such as genomics and proteomics,
which are beginning to provide the complete identification and
function of the genetic and molecular machineries in cancer. This
knowledge will allow a more precise definition of several param-
eters that have influenced tumor dynamic—the mitotic and the
mutation rates, the type and number of mutational events and
the selective forces that occur at each evolutionary stage in a
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particular type of cancer, leading to refined models of tumori-
genesis. Though this represent a good opportunity to develop a
comprehensive model of tumor dynamics, it will still be necessary
to organize this information, and perhaps the most important
goal of high throughput analysis is to determine which changes
matter and which are less important.
POPULATION GENETICS MODELS—DYNAMICS OF GENETIC
VARIATIONWITHIN POPULATION
One of the first mathematical models that explicitly used genome
data to simulate the somatic evolution of colorectal tumor was
proposed by Beerenwinkel et al. (2007). The model was based on
genomic studies of colorectal cancers patients that showed that
mutational patterns among those patients were quite diverse—
estimating as many as∼20 driver mutations per tumor, and those
different landscapes could lead to the same tumor phenotype
(Sjöblom et al., 2006). Hence, the model proposed to investi-
gate the importance of selection (the clonal expansion in the
model), as the driving force in tumor progression, from a benign
tumor (∼1mg or 106 cells) to a full-grown cancer (∼1 gr or 109
cells), over a period of 5–20 years. The tumorigenic progression is
described as a Wright-Fischer process, where cells evolve in non-
overlapping generations and each new cell, generated with the
probability proportional to the parental fitness, can acquire a new
mutationwith “u” probability at each non-mutated gene location.
Employing basic parameters—population size (N), number of
susceptible genes (potential drivers, k), mutation rate (u) and the
fitness advantage (s, always positive), they derive an analytical for-
mula for the expected waiting time for the evolution from benign
to malignant stages. As described by Equation (1) (reproduced
from Beerenwinkel et al., 2007),
tk = k
(
log sud
)2
s log (NinitNfin)
, (1)
the fitness parameter has a major impact on the average waiting
time for the tumor manifestation, with the average time reducing
approximately as 1/s. In contrast, other parameters like mutation
rate and population size have a minor impact—they contribute
only logarithmically. Fitting the model to colon carcinomas data,
they estimated the number of genes involved as 20 and best esti-
mated for fitness parameter as 0.1, in a very good agreement with
the Slobjon study. Although it is widely accepted that the impact
of a specific mutation on phenotype will depend on the genetic
background, the model assumed that each subsequent mutation
has the same incremental effect on the fitness of the cell. It is
important to notice that this model does not exclude the pres-
ence of highly frequent mutations that confers a large growth
advantage to tumor cells, such as APC, K-ras, and p53. Though,
it stresses that the pattern of multiple mutations with a small
and distinct fitness advantage occurring in dozens of genes will
determine and characterize the heterogeneity pattern observed
in any kind of tumor. According to this model, tumorigene-
sis is a dynamical process, where multiple stochastic sequential
mutations contribute for the cancer outcome.
Extending these observations, Jones et al. (2008) inves-
tigated the common mutational patterns during the phases
of tumor initiation, invasion and metastasis, to evaluate the
time extending through each phase. Using an approach they
called “comparative lesion sequencing” they examined quantita-
tively the mutations described in colon cancers genomic studies
(Wood et al., 2007) and in other neoplastic lesions of the same
patients. Hence, they performed a quantitative analysis of data
patterns, to estimate the time intervals required for the appear-
ance of the cells that originate the clonal expansions. The basis
of the model dynamics can be described as follows: in each car-
cinogenic stage (microadenoma, small and large adenoma, early
and advanced carcinoma, metastasis), there is a founder cell
(Fcell) that gives rise to the various tumor populations. During
tumor evolution, cells acquire other mutations andmight become
founder cells of succeeding carcinogenic states. For example, the
time interval between the birthdate of a founder cell for a metas-
tasis (Fcell met) and the founder cell of an advanced carcinoma
(Fcell aca) can be approximated as Equation (2) (reproduced
from Jones et al., 2008).
TACa,Met = FACa,Met · TMet, (2)
An important model premise is the necessity of a constant rate
and time for cell divisions over tumor evolution—a requirement
that seems to be quite reliable, given the good agreement between
the estimated values and the clinical and radiological observa-
tions. One of the main predictions is that it takes much longer
for a large adenoma to evolve onto an advanced carcinoma than
for such carcinoma to metastasize, a result confirmed by simu-
lations where patients data could be applied (patients whom a
minimum of 25 mutations could be evaluated). The results also
indicated that virtually all of the mutations needed for metastasis
are previously settled in all of the cells of the original carcinoma.
According to Jones the data analyzed were compatible with two
distinct models, “in model A, none of the carcinoma cells can give
rise to a metastasis, but they are close to being able to do so; one
or a few more genetic alterations are required. In model B, all of
the carcinoma cells can give rise to metastasis; no more genetic
alterations are required.” Therefore, in a carcinogenic, as well as
in a phylogenetic process, mutations act like a clock, providing
information about the relatedness of organisms or cells during
evolution.
This point was investigated by Yachida et al. (2010), which
used genomic data of seven pancreatic cancer patients present-
ing metastases, to evaluate the clonal relationships among pri-
mary and metastatic cancers. The results showed that the pattern
observed in the cells that originated metastasis were clearly rep-
resented in the cells within the primary carcinoma i.e., itself, a
combination of many distinct subclones, each one with its own
heterogenic pattern. Additionally, using the mathematical model,
they could calculate the elapsed time between the different stages
of the tumorigenic process. The results showed an estimation
very similar to the one reported by Jones et al. (2008), with an
average of 11.7 years from the initiation of tumorigenesis until
the birth of the cell giving rise to the parental clone, an aver-
age of 6.8 years from then until the birth of the cell giving rise
to the index lesion, and an average of 2.7 years from then until
the patients’ death. Taking these correlations as a conservative
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assumption, the knowledge of the dynamics of the tumor pro-
gression, in quantitative terms, offers a chance to interfere in the
tumor evolution and develop a more customized treatment.
In the same line of investigation as Beerenwinkel et al. (2007)
and Bozic et al. (2010) developed a mathematical model to
conciliate cancer genomics data with epidemiologic and clinic
observations. The model is based on a discrete time Galton-
Watson branching process—a stochastic process often used in
population genetics. The model emphasis is in tumor progres-
sion, not initiation. At each iteration, given a certain probability,
a cell can either (1) stagnate (i.e., differentiate, die, or senesce);
(2) divide and the daughter cells maintain the same number of
driver mutation; or (3) divide and daughter cells receive an addi-
tional driver mutation (Figure 1). The simulation begins with a
cell presenting a unique driver mutation and it progresses with an
increasing rate of clonal expansion, as the cells acquire new driver
mutations. The underlying assumption is that a driver mutation
reduces the chance for cell stagnation and enhances their “fitness.”
Again, the model dynamics depend on only three parameters:
the average driver mutation rate (u), the average selective advan-
tage associated with driver mutation (s), and the average cell
division time (T). Using an estimated average mutation rate per
cell division of 3.4 × 10−5, one can calculate the average time
between the appearances of successful cell lineages, and there-
fore, the acquisition of subsequent driver mutations, as shown in
Equation (3) (reproduced from Bozic et al., 2010). Moreover, one
can also calculate the number of passenger mutations in a par-
ticular tumor, taking the selective advantage that a single driver
mutation awards to the tumorigenic cell.
tk = T
ks
log
2ks
u
, (3)
The model was verified both qualitatively and quantitatively
by comparing clinical mutation data from glioblastoma multi-
forme and pancreatic adenocarcinoma, the most common type of
tumor in brain and pancreas, respectively, with the data obtained
by simulation. Fitting the model parameters to the numbers of
driver mutations from clinical data, the average selective advan-
tage of a driver mutation was estimated as 0.4%, for both tumors.
This value was confirmed by a best-fit parameter analysis for
glioblastoma and pancreatic cancers, using the same mutation
rate. Besides, they observed that changing the mutation rate (u) in
two orders of magnitude—from 10−4 to 10−6, resulted in an aver-
age selective advantage (v) of 0.65 and 0.32%, respectively. This
remarkable consistency of the v parameter seems to represent at
least the magnitude of the advantage that the driver mutations
confer to a tumor cell, which seems to be very small (0.4%). This
has a direct implication on the pace development that is observed
within any type of tumor. Since more than 99% of driver muta-
tions become extinct, the probability of a clonal expansion from
a single driver mutation is almost null.
Despite the oversimplifications and limiting assumptions, con-
cerning the fixed life spam of tumor cells, the exponential growth
patterns of the tumor and specially, the constant fitness value of
driver mutations, the model captures several essentials character-
istics of tumor growth in a more quantitative scenario. Besides,
FIGURE 1 | Schematic representation of branching process model of
cell division, as proposed by Bozic et al. (2010). According to a specific
probabilistic distribution, each cell can either (1) die, (2) divide without
acquisition of a new mutation, or (3) divide with acquisition of a new driver
mutation.
it puts into perspective the complexity of cancer biology (as
any other biological process) with all factors concourse for the
tumorigenic process—the cell fitness, i.e., the cell division rate
and the grow advantage conferred by mutation, and also the envi-
ronment selective pressure. As any type of (theoretical) model,
there will be always the possibility of refinements as long as the
information about the particular system is improved. When the
model hypothesis and previsions are in disagreement with the
observed data, the model structure should be reevaluated in order
to better represent the biological knowledge.
PROSPECTS
Sequencing technologies will continue to progress and this will
affect the waywe diagnose and treat tumors in a dramatic fashion.
Data generated from thousands, or even millions, of patients will
feed the development of more refined mathematical models of
cancer. For example, it is reasonable to envisage that soon we will
have the genomes of several tumor cells within the same tumor
due to the development of whole-genome sequencing strategies
for single cells. With that, we will have more precise information
on the level of genetic heterogeneity within a tumor. Furthermore,
that will allow the characterization, in quantitative terms, of
all the evolutionary forces acting on tumor cells in a temporal
fashion. For example, it is expected that the frequency of a given
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passenger mutation will fluctuate within the tumor in a way sim-
ilar to a neutral mutation in a population, i.e., driven by random
drift. That type of information will allow the development of
more precise mathematical models.
Another important issue is the integration of more precise
clinical data. With cancer genomes being sequenced, associations
between genetic and clinical patterns will become more sounded.
Ultimately, the goal of any mathematical modeling of the tumori-
genic process is to predict what genetic alterations are predictive
of any important clinical feature. Associations between these
genetic alterations and clinical phenotypes are therefore very
important in the mathematical modeling of tumors.
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